Nucleic acid-based nanotherapeutics for treating sepsis and associated organ injuries

• Published in: Theranostics Vol. 14; no. 11; pp. 4411 - 4437
• Main Authors: Yu, Huang-Ping, Liu, Fu-Chao, Chung, Yu-Kuo, Alalaiwe, Ahmed, Sung, Calvin T, Fang, Jia-You
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher 01.01.2024
• Subjects: Animals; Gene Transfer Techniques; Genetic Therapy - methods; Humans; Multiple Organ Failure - drug therapy; Multiple Organ Failure - therapy; Nanoparticles - chemistry; Nucleic Acids - administration & dosage; Nucleic Acids - therapeutic use; Review; Sepsis - drug therapy; Sepsis - therapy; nanoparticle; multiple organ dysfunction; nucleic acid delivery; nucleic acid; bacteria; sepsis
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.98487

In recent years, gene therapy has been made possible with the success of nucleic acid drugs against sepsis and its related organ dysfunction. Therapeutics based on nucleic acids such as small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNAs (mRNAs), and plasmid DNAs (pDNAs) guarantee to treat previously undruggable diseases. The advantage of nucleic acid-based therapy against sepsis lies in the development of nanocarriers, achieving targeted and controlled gene delivery for improved efficacy with minimal adverse effects. Entrapment into nanocarriers also ameliorates the poor cellular uptake of naked nucleic acids. In this study, we discuss the current state of the art in nanoparticles for nucleic acid delivery to treat hyperinflammation and apoptosis associated with sepsis. The optimized design of the nanoparticles through physicochemical property modification and ligand conjugation can target specific organs-such as lung, heart, kidney, and liver-to mitigate multiple sepsis-associated organ injuries. This review highlights the nanomaterials designed for fabricating the anti-sepsis nanosystems, their physicochemical characterization, the mechanisms of nucleic acid-based therapy in working against sepsis, and the potential for promoting the therapeutic efficiency of the nucleic acids. The current investigations associated with nanoparticulate nucleic acid application in sepsis management are summarized in this paper. Noteworthily, the potential application of nanotherapeutic nucleic acids allows for a novel strategy to treat sepsis. Further clinical studies are required to confirm the findings in cell- and animal-based experiments. The capability of large-scale production and reproducibility of nanoparticle products are also critical for commercialization. It is expected that numerous anti-sepsis possibilities will be investigated for nucleic acid-based nanotherapeutics in the future.